Sidley represented Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate.
Janssen agreed to pay Yuhan $50 million in upfront money with the potential for significant milestone and royalty payments that could amount to the total of $1.25 billion if the drug earns regulatory approval.
The deal was led by partner Josh Hofheimer (Picture) with counsel Lauren Grau (Dallas).
Law Firms: Sidley Austin LLP;
Clients: Yuhan Corporation;